Last reviewed · How we verify

NCT04970004

Study in Adult and Pediatric Patients With HSCT-TMA

Withdrawn Last updated 12 May 2022
What this trial tests

trial testing No intervention in Stem Cell Transplant Complications. Withdrawn.

Timeline
12 July 2021
Primary endpoint
1 April 2022
1 April 2022

Quick facts

Lead sponsorAlexion Pharmaceuticals, Inc.
StatusWithdrawn
Study typeOBSERVATIONAL
Start date12 July 2021
Primary completion1 April 2022
Estimated completion1 April 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Alexion Pharmaceuticals, Inc. — full company profile →

Who can join

1 Month and older, any sex, with Stem Cell Transplant Complications or Thrombotic Microangiopathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, retrospective study designed to assess outcomes in patients diagnosed with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) who were not treated with complement component (C5) inhibitor therapy. Data required to evaluate study outcomes will be abstracted from the medical records of all patients who meet study eligibility criteria.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Stem Cell Transplant Complications

Currently open trials in the same condition.

Other Alexion Pharmaceuticals, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04970004.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing